Abstract 237TiP
Background
An integrated precision oncology approach that can guide the selection of personalized therapy is paramount to achieving improved outcomes in patients while maintaining responsible healthcare economics. Actionable precision oncology requires in vitro diagnostic tests that are sufficiently sensitive, accurate, reproducible, and reliable in the real-world setting with minimal risk of patient overtreatment or undertreatment. Liquid biopsies and specifically ctDNA based diagnostics provide a unique opportunity to optimize clinical decisions and thereby improve individual patient care. Such techniques could be particularly valuable in the adjuvant setting where multi-modal therapy (MMT) has curative potential. Multiple studies provide evidence that serial ctDNA monitoring can predict or detect recurrence earlier than conventional surveillance. However, as highlighted in the most recent ESMO ctDNA recommendations, the detection limit of current diagnostics to accurately report ctDNA fragments in peripheral blood remains a challenge. Importantly, it is currently unclear how to incorporate ctDNA as MRD biomarker or as a decision tool for treatment selection to improve cancer outcomes. GUIDE.MRD, a patient-centered precision oncology public-private partnership under the Innovative Health Initiative umbrella, is designed to improve the utility and clinical implementation of ctDNA as MRD biomarker and to evaluate the potential of novel decision tools to match patients to MMTs.
Trial design
Partners from academic, medical technology, pharmaceutical and patient advocacy sectors will join to (a) benchmark available ctDNA assays for sensitivity, specificity, and predictive value using reference material that closely mimic patient samples in the adjuvant setting, (b) to clinically validate the top performing ctDNA assay characteristics in patients with NSCLC, CRC and PDAC and develop patient-centric clinical implementation roadmaps, and (c) determine the utility of ctDNA assays as a prospective decision tool of clinical response and choice of MMT including novel combinations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Universitaetsklinikum Hamburg-Eppendorf.
Funding
Innovative Health Initiative.
Disclosure
K. Pantel: Financial Interests, Personal, Invited Speaker, Research Presentation and Discussion: Abcam, Agena, Ipsen Pharma, Medac; Financial Interests, Personal, Advisory Board: Hello Healthcare, Sanofi; Financial Interests, Personal, Advisory Board, Research Presentation and Discussion: Menarini; Financial Interests, Personal, Advisory Board, Expert Input Forum: MSD; Financial Interests, Institutional, Other: Angle plc; Financial Interests, Institutional, Other, Clinical study: Boehringer Ingelheim; Financial Interests, Institutional, Other, UKE - European Liquid Biopsy Society (ELBS): ELBS; Financial Interests, Institutional, Other, EFPIA Partners of EU/IMI Cancer-ID consortium: UKE - European Liquid Biopsy Society (ELBS). C. Lindbjerg Andersen: Non-Financial Interests, Institutional, Funding: Natera, C2i Genomics. E. Schuuring: Financial Interests, Institutional, Research Grant: Abbott, Biocartis, AstraZeneca, Invitae/Archer, Bayer, Bio-Rad, Roche, Agena Bioscience, CC Diagnostics, MSD/MERCK, Boehringer Ingelheim; Financial Interests, Institutional, Advisory Board: MSD/Merck, AstraZeneca, Roche, Novartis, Bayer, BMS, Lilly, Amgen, Illumina, Agena Bioscience, CC Diagnostics, Janssen Cilag (Johnson&Johnson), Astellas Pharma; Financial Interests, Institutional, Invited Speaker: Bio-Rad, Seracare, Roche, Biocartis, Lilly, Agena Bioscience, Illumina; Financial Interests, Institutional, Other, Only travel expenses: BioRad, Biocartis, Ageno Sciences; Non-Financial Interests, Personal, Member of Board of Directors: Dutch Society of Pathology, European Society of Pathology, European Liquid Biopsy Society; Financial Interests, Personal and Institutional, Advisory Role: Advisory committee for assessment of molecular diagnostics (cieBOD; secretary/member), National guideline advisory committee member. N. Malats: Non-Financial Interests, Personal, Other, Partner GUIDE-MRD: Spanish National Cancer Research Centre (CNIO). E. Heitzer: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Institutional, Research Grant: Roche, Illumina, PreAnalytiX. E. Kiernan: Financial Interests, Personal, Full or part-time Employment: Illumina Inc. E. Chin: Financial Interests, Institutional, Full or part-time Employment: Revvity; Financial Interests, Institutional, Stocks/Shares: Revvity. J.C. Barrett: Financial Interests, Institutional, Full or part-time Employment: AstraZenenca. J.R. Kapp: Financial Interests, Personal, Full or part-time Employment: Amgen Inc.; Financial Interests, Personal, Stocks/Shares: Amgen Inc. M. Thomas: Financial Interests, Institutional, Full or part-time Employment: F. Hoffmann La Roche; Financial Interests, Institutional, Member: F. Hoffmann La Roche; Financial Interests, Institutional, Stocks/Shares: F. Hoffmann La Roche. M. Gerling: Financial Interests, Institutional, Local PI: IHI-EU project GUIDE.MRD. M. Reck: Financial Interests, Personal and Institutional, Invited Speaker: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, GSK, Lilly, Mirati, MSD, Merck, Novartis, Regeneron, Sanofi, Roche; Financial Interests, Personal and Institutional, Speaker’s Bureau: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, GSK, Lilly, Mirati, MSD, Merck, Novartis, Regeneron, Sanofi, Roche; Financial Interests, Personal and Institutional, Advisory Board: Amgen, AstraZeneca, BMS, Biontech, Boehringer Ingelheim, Daiichi Sankyo, Gilead, GSK, MSD, Mirati, Pfizer, Regeneron, Sanofi, Roche; Financial Interests, Personal and Institutional, Other, DMSB: Daiichi Sankyo, Sanofi. P. Hofman: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Qiagen, AbbVie, Novartis, Janssen; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Qiagen, AbbVie, Novartis, Janssen. J.T.J.N. Hiltermann: Financial Interests, Personal and Institutional, Other: Roche, BMS, MSD, Pfizer, CieBOM, GSK, Novartis, Merck Serono, Amgen; Financial Interests, Personal and Institutional, Advisory Role: AstraZeneca, Bristol Myers Squibb, Merck Sharp Dohme, Roche; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca, Hoffmann-La Roche. C. Alix-Panabières: Financial Interests, Personal, Other: Menarini, CTC technologies. M. Bolisetty: Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb. M. Karasarides: Financial Interests, Institutional, Full or part-time Employment: Bristol Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
253P - Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK
Presenter: Vasileios Angelis
Session: Poster session 02
254P - Effects of delaying adjuvant chemotherapy initiation on clinical outcomes in early triple-negative breast cancer patients
Presenter: Maria Eleni Hatzipanagiotou
Session: Poster session 02
255P - Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 02
256P - Evolution and risk stratification of adjuvant treatment strategies for early breast cancer: A Chinese perspective based on a national cancer database
Presenter: Ying Fan
Session: Poster session 02
257P - The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
Presenter: Bo Lan
Session: Poster session 02
258P - Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
Presenter: Ricardo Brugés Maya
Session: Poster session 02
259P - Adjuvant doxorubicin-cyclophosphamide in early-stage breast cancer provides long-term cardiac safety
Presenter: Thiti Susiriwatananont
Session: Poster session 02
260P - Oncology efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Presenter: Hee Jun Choi
Session: Poster session 02
261P - Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
Presenter: Bernardo Rapoport
Session: Poster session 02